Vsevolod Rudoy
Psychiatry · Brooklyn, NYNPI 1619920113
Payments from drug & device makers
Across 452 payments — averaging $25.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Neos Therapeutics, LP$1K
- Lundbeck LLC$944
- Supernus Pharmaceuticals, Inc.$847
- AbbVie$819
- plus $5K from 25 others
What the payments were for
- Speaking & faculty fees$5004%
- Food & beverage$10,80295%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 54 | $1,977 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $1,086 |
| Neos Therapeutics, LP | 75 | $1,066 |
| Lundbeck LLC | 55 | $944 |
| Supernus Pharmaceuticals, Inc. | 12 | $847 |
| AbbVie(2 entities) | 34 | $819 |
| Corium, LLC | 30 | $758 |
| Neurocrine Biosciences, Inc. | 5 | $610 |
| Johnson & Johnson | 10 | $518 |
| Bausch Health US, LLC | 25 | $481 |
| Sunovion Pharmaceuticals Inc. | 24 | $480 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $475 |
| Shire North American Group Inc | 21 | $276 |
| Almatica Pharma LLC | 5 | $127 |
| Tris Pharma Inc | 6 | $108 |
| Brainsway USA Inc | 2 | $89 |
| Vanda Pharmaceuticals Inc. | 4 | $80 |
| Idorsia Pharmaceuticals US Inc | 4 | $78 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Ironshore Pharmaceuticals Inc. | 3 | $69 |
| Noven Therapeutics, LLC | 3 | $59 |
| Biogen | 2 | $49 |
| Jazz Pharmaceuticals Inc. | 2 | $47 |
| Alkermes, Inc. | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Neuronetics, Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$682
- INGREZZA$588
- REXULTI$525
- ABILIFY MAINTENA$520
- SPRAVATO$388
- CAPLYTA$384
- ABILIFY ASIMTUFII$270
- Azstarys$244
- VRAYLAR$134
- LATUDA$125
- ABILIFY MYCITE$123
How this compares
$11,311 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 13 | $15,662 |
| VraylarCariprazine Hcl | 11 | $15,315 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $1,980 |
| Atomoxetine Hcl | 11 | $1,354 |
| Fluvoxamine Maleate | 12 | $892 |
| Sertraline Hcl | 48 | $649 |
| Trazodone Hcl | 45 | $577 |
| Clonazepam | 78 | $520 |
| Bupropion XlBupropion Hcl | 42 | $463 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 18 | $462 |
| Mirtazapine | 30 | $452 |
| Prazosin Hcl | 23 | $445 |
| Lorazepam | 29 | $387 |
| Temazepam | 12 | $254 |
| Dextroamphetamine Sulfate | 17 | $244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,977 | $15,66213 claims |
| AbbVieVraylar | $819 | $15,31511 claims |
| Almatica Pharma LLCSertraline Hcl | $127 | $64948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Brooklyn
- Inna Yuryev-GolgerBrooklyn$3M
- Zinoviy BenzarBrooklyn$505K
- Nikhil PalekarBrooklyn$481K
- Mark OwensBrooklyn$286K
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.